What is ContraFect Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ContraFect's interest expense for the
three
months ended in Sep. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ContraFect's Operating Income for the
three
months ended in Sep. 2023 was $ -6.68 Mil. ContraFect's Interest Expense for the
three
months ended in Sep. 2023 was $ 0.00 Mil.
GuruFocus does not calculate ContraFect's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ContraFect Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ContraFect (OTCPK:CFRXQ) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ContraFect's Interest Expense for the
three
months ended in Sep. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Sep. 2023 was $-6.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2023 was $1.87 Mil.
ContraFect's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as
| GuruFocus does not calculate ContraFect's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. ContraFect Corp has enough cash to cover all of its debt. Its financial situation is stable.
ContraFect (ContraFect) Business Description
Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
| Jane F Barlow |
director |
6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
| Lishan Aklog |
director |
420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
| Michael Messinger |
officer: VP Finance |
238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534 |
| Cary Sucoff |
director |
1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904 |
| David N. Low |
director |
EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111 |
| Sol J Barer |
director |
C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
| Lisa Ricciardi |
director |
C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
| Joshua B Muntner |
officer: SVP Business Development |
30 FIFTH AVENUE, 12F, NEW YORK NY 10011 |
| Shanghai Fosun Pharmaceutical (group) Co., Ltd. |
10 percent owner |
BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233 |
| Fosun Industrial Co., Ltd |
10 percent owner |
FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000 |
| Cara M Cassino |
officer: Chief Medical Officer |
757 STONY POINT ROAD, BENSON VT 05743 |
| Natalie Bogdanos |
officer: General Counsel |
207-23 DARREN DRIVE, BAYSIDE NY 11360 |
| Roger Pomerantz |
director |
711 HARVEST HILL ROAD, CHALFONT PA 18914 |
| Michael J. Otto |
director |
303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
| Steven C Gilman |
director |
110 HARTWELL AVENUE, LEXINGTON MA 02421 |
ContraFect (ContraFect) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CFRXQ has been successfully added to your 